A third generation cephalosporin will have more gram negative coverage than a first generation cephalosporin.

Rationale: A. As cephalosporin development progressed from first to third generations, the spectrum of activity was specifically engineered to increase efficacy against Gram-negative bacilli. Third-generation agents, such as ceftriaxone, can penetrate the outer membrane of Gram-negative organisms more effectively and resist many beta-lactamases. This expanded coverage makes them suitable for treating serious infections like meningitis or sepsis caused by enteric Gram-negative pathogens. B. First-generation cephalosporins actually possess the most potent coverage against Gram-positive cocci, such as Staphylococcus aureus and Streptococcus pyogenes. As the generations advance toward the third and fourth, there is often a relative trade-off where Gram-positive activity is slightly diminished compared to the earliest agents. Therefore, a third-generation drug would not be described as having "more" Gram-positive coverage than a first-generation drug. C. Cephalosporins, regardless of their generation, lack clinical activity against atypical pathogens such as Mycoplasma pneumoniae or Legionella. These organisms either lack a traditional peptidoglycan cell wall or reside intracellularly, rendering beta-lactam antibiotics ineffective. To treat atypical infections, clinicians must utilize different drug classes like macrolides or tetracyclines that target protein synthesis rather than cell wall construction. D. Cephalosporins are strictly antibacterial agents and possess no pharmacological activity against fungal organisms like Candida or Aspergillus. Fungal cells have a chitin-based cell wall and different metabolic pathways that are not affected by beta-lactam rings. Using an antibacterial for a fungal infection is inappropriate and can lead to secondary complications like the overgrowth of opportunistic fungal species in the patient.